Literature DB >> 17138806

Population pharmacokinetics in geriatric psychiatry.

Kristin L Bigos1, Robert R Bies, Bruce G Pollock.   

Abstract

Although geriatric patients are the major recipients of drugs, most research during drug development is conducted in healthy younger adults. Safe and effective drug therapy in the elderly requires an understanding of both drug disposition and response in older individuals. One of the major issues in studying the elderly relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics can be used to model drug concentrations from a large population of sparsely sampled individuals. Population pharmacokinetics characterizes both the interindividual (between-subject) and intraindividual (within-subject) variability, and can identify factors that contribute to pharmacokinetic and pharmacodynamic variability. Population pharmacokinetics can be used to aid in designing large clinical trials by simulating virtual data based on the study design. It can also be used to assess consistency of drug exposure and evaluate its effect on clinical outcome. This article reviews the methods used in pharmacokinetic modeling, as well as providing examples of population pharmacokinetic modeling, highlighting its application to geriatric psychiatry.

Entities:  

Mesh:

Year:  2006        PMID: 17138806     DOI: 10.1097/01.JGP.0000224330.73063.6c

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  6 in total

Review 1.  Pharmacokinetics in geriatric psychiatry.

Authors:  Kristin L Bigos; Marci L Chew; Robert R Bies
Journal:  Curr Psychiatry Rep       Date:  2008-02       Impact factor: 5.285

2.  Health outcomes associated with potentially inappropriate medication use in older adults.

Authors:  Donna M Fick; Lorraine C Mion; Mark H Beers; Jennifer L Waller
Journal:  Res Nurs Health       Date:  2008-02       Impact factor: 2.228

3.  Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

Authors:  Hitoshi Sakurai; Robert R Bies; Scott T Stroup; Richard S E Keefe; Tarek K Rajji; Takefumi Suzuki; David C Mamo; Bruce G Pollock; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2012-01-30       Impact factor: 9.306

4.  What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly.

Authors:  Tao Xiao; Zhanzhang Wang; Guanlie Li; Shanqing Huang; Xiuqing Zhu; Shujing Liu; Xiaolin Li; Jinqing Hu; Dewei Shang; Yuguan Wen
Journal:  Drug Des Devel Ther       Date:  2021-08-04       Impact factor: 4.162

5.  Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Authors:  Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Res       Date:  2014-02-01       Impact factor: 4.939

6.  Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.

Authors:  Alastair J Flint; Barnett S Meyers; Anthony J Rothschild; Ellen M Whyte; Benoit H Mulsant; Matthew V Rudorfer; Patricia Marino
Journal:  BMC Psychiatry       Date:  2013-01-25       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.